Verona Pharma: A 363% Return Thanks To Big Pharma's Myopia
Merck plans to acquire Verona Pharma for $10 billion, or $107 per share — a 363% gain for the Innovation & Freedom Portfolio.
Portfolio Update: Is This The Peak (For Now)?
Since its inception in August 2024, the I&F Portfolio has gained over 100%, outpacing the S&P 500 by 85%, driven by standout performances from Rocket Lab (RKLB), Verona Pharma (VRNA), Navitas Semiconductor (NVTS), and others.
America Was Great When She Was Good
America must balance protecting her interests while maintaining the moral principles that made her great, or risk losing both her greatness and the world order she created.
The Greatest Bull Trap Of All Time?
The recent market rally seems like a house of cards, built on a single optimistic narrative. The slightest crack in this best-case scenario could trigger a wave of profit-taking, causing the rally to turn into a monumental bull trap.
Memories In Ligne Claire With OpenAI's 4o Image Generation
The internet went crazy after the release of OpenAI's 4o Image Generation last week. I love the style of Belgian comic artist Hergé and had 4o convert some of my photos into a Ligne Claire style. The results are beautiful.
Why Estimates For NVIDIA's Q4 Revenue Could Be Dead Wrong: The Case for NVIDIA's Next Blowout Report
Estimating NVIDIA's Q4 2025 revenue from the capex of its four largest customers using linear regression results in an estimated revenue that is significantly higher than Wall Street's expectations.
Powell Industries: Rooted in The Oil Boom, Ready For The AI Revolution
Powell Industries is poised to benefit from the growing need for sophisticated power distribution solutions for AI data centers, reshored manufacturing driven by robotics and automation, and a booming nuclear energy sector.
NVIDIA: No Reason To Panic
The recent sell-off in NVIDIA shows one thing above all, in my opinion: many of today's investors do not understand the companies they are investing in.
Jevons Paradox: DeepSeek-R1 Will Ultimately Drive Demand for NVIDIA's GPUs
In 1865, William Jevons observed that coal consumption in England was growing exponentially despite increasingly efficient steam engines. Similarly, in the coming years, more efficient AI models like DeepSeek-R1 could drive demand for NVIDIA's GPUs, not reduce it.
DeepSeek-R1 Clearly Outperformed OpenAI's o1 pro mode In My Ant Sim Test
I tested DeepSeek-R1 against OpenAI's o1 pro mode by having both program an ant simulation from the same prompt. DeepSeek-R1 generated a far superior simulation. As AI models become increasingly commoditized, I think this shows again that AI is a hardware revolution, not a software revolution.
Journey Medical Corporation: Why It Might Be Worth Having A Skin In This Game
Journey Medical's newly approved Emrosi™ outperformed Oracea® in two Phase III trials. If it captures a significant share of Oracea's $300m market, Journey could be significantly undervalued.
Hermès International: Why Artisan Craftsmanship Is A Bet On The Dawning Technological Revolution
At the dawn of the AI age, Hermès is still focusing on craftsmanship and scarcity, which could make its luxury products increasingly desirable and valuable, especially in an era of rapid automation and commoditization of goods.